Cancer-Associated Fibroblasts in Mycosis Fungoides Promote Tumor Cell Migration and Drug Resistance through CXCL12/CXCR4

Cancer cells are known to reprogram normal fibroblasts into cancer-associated (CAFs) act as tumor supporters. The presence and role of CAFs in mycosis fungoides (MF), the most common type cutaneous T-cell lymphoma, unknown. This study sought characterize MF their cross talk with lymphoma using primary fibroblast cultures from punch biopsies patients early-stage healthy subjects. yielded significantly increased levels FAP?, a CAF marker, CAF-associated genes proteins: CXCL12 (ligand CXCR4 expressed on cells), collagen XI, matrix metalloproteinase 2. Cultured showed greater proliferation than ex vivo experiments. A coculture MyLa (MF cell line) growth, reduced sensitivity doxorubicin, enhanced migration. Inhibiting CXCL12/CXCR4 axis doxorubicin-induced apoptosis motility. Our data suggest that lesions more proliferative skin protect death increase migration through secretion CXCL12. Reversing CAF-mediated microenvironment may improve efficiency anticancer therapy. Primary lymphomas heterogeneous group extranodal non-Hodgkin (Rosen Querfeld, 2006Rosen S.T. Querfeld C. lymphomas.Hematology Am Soc Hematol Educ Program. 2006; 2006: 323-330Crossref Scopus (32) Google Scholar). Mycosis (MF) is accounting for 60% all patients. It presents early indolent stage patches and/or plaques, whereas advanced characterized by appearance tumors or erythroderma, rare involvement blood, lymph nodes, viscera. immune has been extensively studied. In MF, antitumor response mediated cytotoxic CD8+ T NK (Torrealba et al., 2017Torrealba M.P. Manfrere K.C. Miyashiro D.R. Lima J.F. de M. Oliveira L. al.Chronic activation profile circulating Sézary syndrome.Oncotarget. 2017; 9: 3497-3506Crossref PubMed (12) Scholar) benign regulatory cells, which have found infiltrate epidermis dermis further counteract malignant expansion (Krejsgaard 2012Krejsgaard T. Odum N. Geisler Wasik M.A. Woetmann A. Regulatory immunodeficiency syndrome.Leukemia. 2012; 26: 424-432Crossref (76) During disease progression, lose diversity, skewing system protective helper 1 an immunosuppressive 2 (Campbell 2010Campbell J.J. Clark R.A. Watanabe R. Kupper T.S. syndrome arise distinct subsets: biologic rationale clinical behaviors.Blood. 2010; 116: 767-771Crossref (327) Scholar; Wilcox, 2017Wilcox Cutaneous lymphoma: 2017 update diagnosis, risk-stratification, management.Am J Hematol. 92: 1085-1102Crossref (80) addition, there decrease tumor-infiltrating shift toward phenotype Tiemessen 2006Tiemessen M.M. Mitchell T.J. Hendry Whittaker S.J. Taams L.S. John S. Lack suppressive CD4+CD25+FOXP3+ stages lymphoma.J Invest Dermatol. 126: 2217-2223Abstract Full Text PDF (86) Studies lesioned report exhaustion activated CD4? CD8? exacerbates progresses (Wong 2011Wong H.K. Mishra Hake Porcu P. Evolving insights pathogenesis therapy (mycosis Sezary syndrome).Br Haematol. 2011; 155: 150-166Crossref (111) However, stroma largely consists meshwork extracellular (ECM) molecules stromal addition cells. Fibroblasts one abundant types microenvironment. Early studies regulate 2?dominant high expression eotaxin-1 eotaxin-3, ligands CCR3 (Miyagaki Sugaya, 2014Miyagaki Sugaya Immunological milieu syndrome.J 2014; 41: 11-18Crossref (37) recent years, cumulative evidence breast, pancreatic, hematological malignancies suggested cancer supporters (Erez 2013Erez Glanz Raz Y. Avivi Barshack I. associated express pro-inflammatory factors human breast ovarian tumors.Biochem Biophys Res Commun. 2013; 437: 397-402Crossref Kalluri, 2016Kalluri biology function cancer.Nat Rev Cancer. 2016; 16: 582-598Crossref (1613) Kobayashi 2019Kobayashi H. Enomoto Woods S.L. Burt A.D. Takahashi Worthley D.L. Cancer-associated gastrointestinal Gastroenterol Hepatol. 2019; 282-295Crossref (149) von Ahrens 2017von D. Bhagat T.D. Nagrath Maitra Verma pancreatic cancer.J Oncol. 10: 76Crossref (186) released play essential roles angiogenesis, metastasis, resistance, maintenance desmoplastic niche ensure survival (O’Donnell 2019O’Donnell J.S. Teng M.W.L. Smyth M.J. immunoediting resistance cell-based immunotherapy.Nat Clin 151-167Crossref (427) Although wiry fibroplasia (Guitart 2001Guitart J. Kennedy Ronan Chmiel Hsiegh Y.C. Variakojis Histologic criteria diagnosis fungoides: proposal grading standardize pathology reporting.J Cutan Pathol. 2001; 28: 174-183Crossref (85) accepted minor criterion possible general particular, not investigated. aim this was mutual interaction features lymphoid Punch without were analyzed commonly used markers (Nurmik 2020Nurmik Ullmann Rodriguez F. Haan Letellier E. search definitions: markers.Int 2020; 146: 895-905Crossref (109) results higher proportion positive FAP?-stained spindle upper tissue (Figure 1a–d) 1e) (79.2% vs. 31.3%, P ? 0.005). FAP? positivity also noted keratinocytes attributed prominent background noise signals indeed some physiological signal relevance MF. based observations few relevant literature negative-to-moderate staining samples, mainly basal adjacent layer (Costa 2018Costa Kieffer Scholer-Dahirel Pelon Bourachot B. Cardon al.Fibroblast heterogeneity environment cancer.Cancer Cell. 2018; 33: 463-479.e10Abstract (493) Staining another ?-smooth muscle actin (Nishishita 2018Nishishita Morohashi Seino Wu Yoshizawa Haga al.Expression colorectal cancer.Oncol Lett. 15: 6195-6202PubMed Scholar), significant between-group difference (data shown). culture (MF-Fs) demonstrated gene compared control subjects (N-Fs) 1f). Analysis ECM (Omland 2017Omland S.H. Wettergren E.E. Mollerup Asplund Mourier Hansen A.J. al.Cancer carcinoma peritumoural [published correction appears BMC 2018;18:111].BMC 17: 675Crossref (27) (MMP)2, MMP9, XI performed quantitative RT-PCR. MMP2 (fold change 2.36; Figure 2a) 39.8; 2d), no MMP9 On western blot analysis cultures, MF-Fs protein relative N-Fs 2b c). Immunohistochemistry confirmed intracellular form (pro-collagen XI) (87.2% 30.5%, 0.005; 2e f). Four immune-regulator genes, IL-1B, IL-6, TGF?1, CXCL12, selected basis previous publications 2010Erez Truitt Olson Hanahan incipient neoplasia orchestrate tumor-promoting inflammation NF-?B-dependent manner Cell 2010;17:523. Arron, Sarah Tuttleton [added]].Cancer 135-147Abstract (1004) Orimo 2005Orimo Gupta P.B. Sgroi D.C. Arenzana-Seisdedos Delaunay Naeem al.Stromal present invasive carcinomas promote growth angiogenesis elevated SDF-1/CXCL12 secretion.Cell. 2005; 121: 335-348Abstract (2723) RT-PCR culture. We only chemokine be involved invasion metastasis several (Domanska 2013Domanska U.M. Kruizinga R.C. Nagengast W.B. Timmer-Bosscha Huls G. Vries E.G.E. al.A review CXCR4/CXCL12 oncology: place hide.Eur 49: 219-230Abstract (407) upregulated 3a). Accordingly, ELISA detected level supernatants 3b). upregulation immunohistochemistry, percentage CXCL12-positive (88.7% 36.6%, < 0.05; 3c d). controls, similar proteins, relatively number overexpressing rate tested cultures. After 72 96 hours counterparts 4a). To determine transforming surrounding highly CAFs, we impact MyLa, line, N-Fs. cocultured had cultured alone. Culturing peripheral blood mononuclear (PBMCs) effect 4b). No seen between those Coculture potential contribution chemoresistance multiple GFs cytokines, previously other (Tao 2017Tao Huang Song Chen fibroblasts: microenvironment.Oncol 14: 2611-2620Crossref (171) alone treated doxorubicin (Doxo) at concentrations 2.5–160 nM viability Proliferation Kit II (XTT) assay. Through entire range Doxo concentrations, resistant 4c). shown Supplementary S1. These might salvage treatment. next step, signaling Previous secreted binds regulating (Sun 2010Sun X. Cheng Hao Zheng Zhou Zhang al.CXCL12 / CXCR7 progression Metastasis 2011;30:269–70].Cancer Rev. 29: 709-722Crossref (554) Moreover, (Maj 2015Maj Jankowska-Konsur A.M. Ha?o? Wo?niak Z. Plomer-Niezgoda Reich Expression correlations fungoides.Postepy Dermatol Alergol. 2015; 32: 437-442Crossref (18) Both flow cytometry direct immunofluorescence revealed membranal (Supplementary S2). Using assay, identified migrated transwells + cocultures NF-Fs 5a). specific inhibitors containing resulted 5b). findings MF-F–derived MyLa-derived investigate pathway together MF-Fs. (20 nM), inhibitor, inhibitor (25 ?g/ml). dual proliferation, depending 5c). while decreasing when Combined treatment even reduction without. under combined due induction apoptosis. examine latter, conducted Annexin V propidium iodide costaining. led marked each agent 5d). Thus, it synergizes reducing inducing demonstrates population considered originate various including progenitor resident fibroblasts. transformation involves novo genetic epigenetic changes self-regulated regulated (Madar 2013Madar Goldstein Rotter V. ‘Cancer fibroblasts’--more meets eye.Trends Mol Med. 19: 447-453Abstract (255) N-Fs, expected tumor. suggests propelling skin?resident CAFs. line oral squamous (Commandeur 2011Commandeur Ho Gruijl F.R. Willemze Tensen C.P. El Ghalbzouri Functional characterization carcinoma.Exp 20: 737-742Crossref Liu 2006Liu Hu Shen Li S.F. Lin J.W. X.H. al.Separation, cultivation biological characteristics carcinoma-associated fibroblasts.Oral Dis. 12: 375-380Crossref Several mechanisms underline process (Sanford-Crane 2019Sanford-Crane Abrego Sherman M.H. modulators local systemic metabolism.Cancers (Basel). 11: 619Crossref (33) Yu 2014Yu Xiao C.H. Tan L.D. Wang Q.S. X.Q. Feng Y.M. induce epithelial-mesenchymal transition paracrine TGF-? signalling.Br 110: 724-732Crossref (336) include TGF? (Yu EGF, PDGF, FGF2 (Bremnes 2011Bremnes R.M. Dønnem Al-Saad Al-Shibli K. Andersen Sirera al.The prognosis: emphasis non-small lung Thorac 6: 209-217Abstract (358) Wnt7a (Avgustinova 2016Avgustinova Iravani Robertson Fearns Gao Q. Klingbeil al.Tumour cell-derived recruits activates tumour aggressiveness.Nat 7: 10305Crossref (90) Scholar); adhesion ICAM VCAM (Zhu Gong, 2013Zhu X.W. Gong J.P. ICAM-1 occurrence development hepatocellular carcinoma.Asian Pac Prev. 1579-1583Crossref (25) microRNAs miR-155, miR-31, miR-214 (Mitra 2012Mitra A.K. Zillhardt Hua Tiwari Murmann A.E. Peter M.E. al.MicroRNAs Discov. 2: 1100-1108Crossref (235) Yang 2017Yang Ning Ma W. Shao Shu al.Exosomal miRNAs miRNA dysregulation fibroblasts.Mol 148Crossref (110) marker enriched CAF-like skin. Therefore, likely these results, qPCR apparently owing enrichment Considering fact both assays proteins normalized equal assume our controls attributable MF-F fibrillar structural proteoglycans, integrins, proteases provide physical scaffold bind behavior (Wolf Friedl, 2011Wolf Friedl Extracellular determinants proteolytic non-proteolytic migration.Trends Biol. 21: 736-744Abstract (239) Tumor survival, require biomechanical architecture, incorporates linking collagens elongation realignment fiber (Alexander Cukierman, 2016Alexander Cukierman Stromal dynamic reciprocity cancer: intricacies fibroblastic-ECM interactions.Curr Opin 42: 80-93Crossref (77) Malik 2015Malik Lelkes P.I. Biomechanical biochemical remodeling cancer.Trends Biotechnol. 230-236Abstract (184) study, ECM-modulating XI. MMP LOX major synthesizing, assembling, modifying composition organization, leading rigid collagen?cross-linked (Vannucci, 2015Vannucci Stroma active player microenvironment.Cancer Microenviron. 8: 159-166Crossref (38) serves barrier drug penetration (Khawar 2015Khawar I.A. Kim J.H. Kuh H.J. Improving delivery solid tumors: priming microenvironment.J Control Release. 201: 78-89Crossref (291) access stiffened promotes because cross-linked can create paths travel (Egeblad 2010Egeblad Rasch M.G. Weaver V.M. Dynamic interplay evolution.Curr 22: 697-706Crossref (556) Kharaishvili 2014Kharaishvili Simkova Bouchalova Gachechiladze Narsia Bouchal fibroblasts, stress microenvironmental resistance.Cancer Int. 41Crossref (123) taken together, inhibiting turnover combination standard monochemotherapy promising approach improving overexpression characteristic many binding downstream kinase B/MAPK pathway, alterations expression, polymerization, skeleton rearrangement, preclinical models, CXCL12-expressing organs Because important source (Izumi 2016Izumi Ishimoto Miyake Sugihara Eto Sawayama al.CXCL12/CXCR4 integrin ?1 clustering invasiveness gastric cancer.Int 138: 1207-1219Crossref (103) they contributor metastasis. Indeed, tended migrate Inhibition motility migrating finding indicates acts chemoattractant CXCR4-expressing antagonist present. well-known suppresses NF-?B activation, Bcl-2 directly pro-apoptotic BAD (Bcl-xl/Bcl-2?associated promoter), indirect transcription factor cAMP component?binding (Ganju 1998Ganju R.K. Brubaker S.A. Meyer Dutt Qin ?-chemokine, factor-1?, transmembrane G-protein-coupled CXCR-4 receptor transduction pathways.J Biol Chem. 1998; 273: 23169-23175Abstract (AMD3100) prevents antiapoptotic induced but protected Doxo. protection attenuated adding antagonist. supports CAF-derived mediating chemotherapy. numerous support use antagonists disrupt CXCR4-dependent tumor?stroma interactions thus sensitize chemotherapy (Burger Peled, 2009Burger J.A. Peled antagonists: targeting leukemia cancers.Leukemia. 2009; 23: 43-52Crossref (364) Dai, 2017Wu Dai therapeutic response.Cancer 387: 61-68Crossref (490) surprise, absence (i.e., alone), unlike MF-Fs, activating pathways, such EGFR, MAPK, PI3K/protein B (Porcile 2005Porcile Bajetto Barbieri Barbero Bonavia Biglieri factor-1? (SDF-1?/CXCL12) stimulates EGF transactivation.Exp Res. 308: 241-253Crossre